Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Breast cancer in young women has been shown to have an aggressive behavior and poor prognosis. This study aimed to evaluate the outcomes of hormone-receptor (HR)-positive young breast cancer patients treated with neoadjuvant chemotherapy (NAC) and the oncologic efficacy of gonadotropin-releasing hormone (GnRH) agonist.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
ODX is one of several genomic tests that has been developed for the identification of early breast cancer and is currently used worldwide [20x[20]Roberts, M.C., Miller, D.P., Shak, S., and Petkov, V.I. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat. 2017; 163: 303–310Google ScholarSee all References20].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
